Spontaneously Hypertensive Rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1748-1752

  Levin, Raquel ^a   Calzavara, Mariana Bendlin ^a   Santos, Camila Maurício ^a   Medrano, Wladimir Agostini ^a   Niigaki, Suzy Tamie ^a   Abílio, Vanessa Costhek ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amphetamine; Antipsychotics; Prepulse inhibition of startle; Schizophrenia; SHR

Indexed keywords

AMPHETAMINE; CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; METOCLOPRAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DRUG ACTIVITY; MALE; NONHUMAN; PREPULSE INHIBITION; RAT; SCHIZOPHRENIA; SENSORY GATING; SPECIES DIFFERENTIATION; SPONTANEOUSLY HYPERTENSIVE RAT; STARTLE REFLEX; WISTAR RAT;

ACOUSTIC STIMULATION; AMPHETAMINE; ANIMALS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; CLOZAPINE; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; MALE; METOCLOPRAMIDE; RATS; RATS, INBRED SHR; RATS, WISTAR; SCHIZOPHRENIA; SENSORY GATING; STARTLE REACTION;

EID: 79961127762     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.06.003     Document Type: Article

References (46)

1. Abílio V.C., Silva R.H., Carvalho R.C., Grassl C., Calzavara M.B., Registro S., et al. Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia. Neuropharmacology 2004, 47:263-272.
2. Bizot J.C., Chenault N., Houze B., Herpin A., David S., Pothion S., Trovero F. Methylphenidate reduces impulsive behaviour in juvenile Wistar rats, but not in adult Wistar, SHR and WKY rats. Psychopharmacology 2007, 193:215-223.
3. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups and pharmacological studies. Psychopharmacology 2001, 156:234-258.
4. Brody S.A., Geyer M.A., Large C.H. Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology 2003, 169:240-246.
5. Calzavara M.B., Levin R., Medrano W.A., Almeida V., Sampaio A.P.F., Barone L.C., Frussa-Filho R., Abilio V.C. Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats. Behav. Brain Res. 2011, 225:15-22.
6. Calzavara M.B., Medrano W.A., Levin R., Kameda S.R., Andersen M.L., Tufik S., et al. Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?. Schizophr. Bull. 2009, 35:748-759.
7. Casey D.E. Tardive dyskinesia. Psychopharmacology: The Third Generation of Progress., New York 1987, 1411-1419. H.Y. Meltzer (Ed.).
8. Ferguson S.A., Cada A.M. Spatial learning/memory and social and nonsocial behaviors in the spontaneously hypertensive, Wistar-Kyoto and Sprague-Dawley rat strains. Pharmacol. Biochem. Behav. 2004, 77:583-594.
9. Ferguson S.A., Paule M.G., Cada A., Fogle C.M., Gray E.P., Berry K.J. Baseline behavior, but not sensitivity to stimulant drugs, differs among spontaneously hypertensive, Wistar-Kyoto, and Sprague-Dawley rat strains. Neurotoxicology 2007, 29:547-561.
10. Flood D.G., Choinski M., Marino M.J., Gasior M. Mood stabilizers increase prepulse inhibition in DBA/2NCrl mice. Psychopharmacology 2009, 205:369-377.
11. Frau R., Orrù M., Fà M., Casti A., Manunta M., Fais N., et al. Effects of topiramate on the prepulse inhibition of the acoustic startle in rats. Neuropsychopharmacology 2007, 32:320-331.
12. Gardos G., Cole J.O. Neuroleptic-treatment and tardive dyskinesia. Neuroleptic-Induced Movement Disorders, New York 1997, 104-116. R. Yassa, P.V. Nair, D.V. Jeste (Eds.).
13. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156:117-154.
14. Gray N.S., Hemsley D.R., Gray J.A. Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol. Psychiatry Brain Res. 1992, 1:83-89.
15. Gururajan A., Taylor D.A., Malone D.T. Effect of testing conditions on the propsychotic action of MK-801 on prepulse inhibition, social behaviour and locomotor activity. Physiol. Behav. 2010, 99:131-138.
16. Hamm A.O., Weike A.I., Schupp H.T. The effect of neuroleptic medication on prepulse inhibition in schizophrenia patients: current status and future issues. Psychopharmacology 2001, 156:259-265.
17. Hawk L.W., Yartz A.R., Pelham W.E., Lock T.M. The effects of methylphenidate on prepulse inhibition during attended and ignored prestimli among boys with attention-deficit hyperactivity disorder. Psychopharmacology 2003, 165:118-127.
18. Hoffman H.S., Ison J.R. Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol. Rev. 1980, 87:175-189.
19. Kinkead B., Selz K.A., Owens M.J., Mandell A.J. Algorithmically designed peptides ameliorate behavioral defects in animal model of ADHD by an allosteric mechanism. J. Neurosci. Methods 2006, 151:68-81.
20. Kumari V., Sharma T. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology 2002, 162:97-101.
21. Lipska B.K., Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000, 23:223-239.
22. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10:79-104.
23. Ong J.C., Brody S.A., Large C.H., Geyer M.A. An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. J. Pharmacol. Exp. Ther. 2005, 315:1163-1171.
24. O'Tuathaigh C.M., Harte M., O'Leary C., O'Sullivan G.J., Blau C., Lai D., et al. Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice. Eur. J. Neurosci. 2010, 31:349-358.
25. Palmer A.A., Dulawa S.C., Mottiwala A.A., Conti L.H., Geyer M.A., Printz M.P. Prepulse startle deficit in the Brown Norway rat: a potential genetic model. Behav. Neurosci. 2000, 114:374-388.
26. Powell C.M., Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biol. Psychiatry 2006, 59:1198-1207.
27. Queiroz C.M., Piovezan R.D., Frussa-Filho R. Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats. Eur. J. Pharmacol. 1998, 356:105-108.
28. Russell V.A. Neurobiology of animal models of attention-deficit hyperactivity disorder. J. Neurosci. Methods 2007, 161:185-198.
29. Perry W., Minassian A., Feifel D., Braff D.L. Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol. Psychiatry 2001, 50:418-424.
30. Ross J., Castilho V.M., Nobre M.J. Analysis of the chronic intake of withdrawal from diazepam on emotional reactivity and sensory information processing in rats. Prog. NeuroPsychopharmacol. Biol. Psychiatry 2008, 32:794-802.
31. Sagvolden T., Metzger M.A., Schiørbeck H.K., Rugland A.L., Spinnangr I., Sagvolden G. The spontaneously hypertensive rat (SHR) as an animal model of childhood hyperactivity (ADHD): changed reactivity to reinforcers and to psychomotor stimulants. Behav. Neural. Biol. 1992, 58:103-112.
32. Sagvolden T., Sergeant J.A. Attention deficit/hyperactivity disorder - from brain dysfunctions to behaviour. Behav. Brain Res. 1998, 94:1-10.
33. Sams-Dodd F. A test of the predictive validity of animal models of schizophrenia based on phencyclidine and d-amphetamine. Neuropsychopharmacology 1998, 18:293-304.
34. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry 1994, 51:139-154.
35. Swerdlow N.R., Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 1998, 24:285-301.
36. Swerdlow N.R., Braff D.L., Geyer M.A. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav. Pharmacol. 2000, 11:185-204.
37. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 2001, 156:194-215.
38. Swerdlow N.R., Shoemaker J.M., Bongiovanni M.J., Neary A.C., Tochen L.S., Saint Marie R.L. Reduced startle gating after D1 blockade: effects of concurrent D2 blockade. Pharmacol. Biochem. Behav. 2005, 82:293-299.
39. Swerdlow N.R., Light G.A., Cadenhead K.S., Sprock J., Hsieh M.H., Braff D.L. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch. Gen. Psychiatry 2006, 63:1325-1335.
40. Van den Bergh F.S., Bloemarts E., Chan J.S.W., Groenink L., Olivier B., Oosting R.S. Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder. Pharmacol. Biochem. Behav. 2006, 83:380-390.
41. Van den Buuse M. Prepulse inhibition of acoustic startle in spontaneously hypertensive rats. Behav. Brain Res. 2004, 154:331-337.
42. Vendruscolo L.F., Terenina-Rigaldie E., Raba F., Ramos A., Takahashi R.N., Mormede P. A QTL on rat chromosome 7 modulates prepulse inhibition, a neuro-behavioral trait of ADHD, in a Lewis x SHR intercross. Behav. Brain Funct. 2006, 12:2-21.
43. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 2003, 169:257-297.
44. Weiss I.C., Feldon N.J. Environmental animal models for sensorimotor gating deficiencies in schizophrenia: a review. Psychopharmacology 2001, 156:305-326.
45. Wynn J.K., Green M.F., Sprock J., Light G.A., Widmark C., Reist C., et al. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr. Res. 2007, 95:134-142.
46. Zhang J., Forkstam C., Engel J.A., Svensson L. Role of dopamine in prepulse inhibition of acoustic startle. Psychopharmacology 2000, 149:181-188.